Dr Hamid Merchant wearing a suit, blue shirt and a blue tie

Dr Hamid Merchant

Head of Department for Bioscience

Head of Department

Pharmaceutical Formulations and Product Development

Department of Bioscience , School Of Health, Sport And Bioscience

Dr Merchant is the Head of Department for Bioscience at the University of East London. He is a pharmaceutical scientist with experience in drug delivery and product development in industry and academia.

Before joining UEL, Hamid worked for the University of Huddersfield (2013-2023), University College London (2011-2013), and Abbott Laboratories Ltd (2002-2007), where he had various leadership roles.

Qualifications

  • BPharm
  • MPharm
  • PGCHE
  • PhD

Areas Of Interest

Formulation design, biopharmaceutics, pharmacokinetics, bioavailability, bioequivalence, vaccines, medicine quality.

Dr Hamid Merchant wearing a suit, blue shirt and a blue tie

OVERVIEW

Dr Merchant is a pharmaceutical scientist with over 20 years experience in research and development both in industry and academia.

Hamid is the founding editor of the British Journal of Pharmacy, an open science initiative from the University Press, and sits on editorial boards for further two peer-reviewed international scientific journals.

He is a Fellow of the Higher Education Academy (Advance HE), a Scientist at the Royal Pharmaceutical Society of Great Britain (SRPharmS), a Fellow of the Academy of Pharmaceutical Sciences (APS), and a Fellow of the Royal Society for Public Health (FRSPH). Hamid also holds honorary adjunct professorships at the Health Services Academy, Government of Pakistan and the Dow University of Health Sciences, Karachi.

CURRENT RESEARCH

Hamid's research expertise includes novel formulation design, biopharmaceutics, pharmacokinetics, bioavailability, and bioequivalence. He has a particular interest in drug delivery research at the interface of gastroenterology and publishes in various aspects of oral delivery.

Hamid has published extensively (Scopus h-index 24 with over 2000 citations), have a patent granted in GB, EU and the US and two further patents under the PCT stage of prosecution.

COVID-19: the novel coronavirus disease

Dr Merchant has proposed an early intervention therapeutic strategy for COVID-19 to prevent developing a severe disease as an alternative approach to control the pandemic.

Dr Merchant has also been the part of the evidence synthesis group for better use of medicines during COVID-19 and has contributed significantly by publishing in peer-reviewed journals, contributing to the media, and range of public education campaigns, both in English and Urdu languages. A few examples of his COVID-19 contributions include: predicting the mortality benefits of steroids early in the pandemic, the benefits of using inhalable corticosteroids in asthma and COPD patients amid pandemic, a critical review of alcohol based hand sanitisers on the market and formulation approaches to respond to the increasing demand, an early warning in the pandemic against antimalarials as cures for coronavirus, and the review of COVID-19 cases, associated hospitalisation, and mortality.

Formulation development

The advancements in materials sciences and improved understanding of the human gastrointestinal (GI) environment are leading to intelligent design of formulations. The rationale design and selection of delivery technologies improves the performance of orally administered drugs, for example, by improving drug solubility, flux or by delivering it to the specific gastrointestinal regions. His research in formulation sciences offers novel and customised solutions for immediate and delayed release formulations; and drug targeting in GI tract, such as delivery to the colon.

Dissolution and permeation of drugs

Drug dissolution in gastrointestinal fluid and its permeation through the gastrointestinal mucosa is a key consideration for its absorption. Our research continues to explore and develop various in-vitro technologies to provide a reasonable estimation of absorption and help selecting a lead formulation for clinical evaluation. One of his innovative strategies is the exploitation of physiological bicarbonate buffers for dissolution testing. This led to the development of an Auto pH System™ – a robust instrumentation and dynamic dissolution media employing physiological bicarbonate buffers simulating the aboral changes in gastrointestinal pH while dosage form transits down the gut after emptying from stomach (PCT/GB2013/051145).

The system exploits the physiological equilibrium of bicarbonate/carbonic acids to control and manipulate the pH and offers a robust automatic pH control without using conventional nonphysiological acid/base titration techniques. The novel system has numerous applications in drug delivery and has been employed to assess dissolution and drug release from various delivery systems, such as: dissolution screening of drugs and its salt forms, evaluation of gastro-resistant formulations, inter-individual variability of GI pH and transit and consequences on drug release, evaluation of delayed-release formulations for colonic targeting, evaluation of sustained-/controlled-release formulations.

Preclinical models in drug delivery

Pre-clinical testing is paramount for the improved understanding of the behaviour of orally administered drugs. Various animal models are used with the aim to mimic as closely as possible the conditions of the human gastrointestinal tract. The characteristics of the gastrointestinal milieu have a significant influence on orally administered drugs. Therefore, rational selection of animal models for a specific delivery technology is a key to successful translation of preclinical observations to clinic.

We have investigated the gastrointestinal milieu of various animal models, such as mice, rat, guinea pig, rabbit and pig, and their effects on drug solubility and absorption. We have also explored the effects of ageing in gastrointestinal environment of rat in relation to drug delivery. For a complete list of peer-reviewed publications, please refer to the publications section.

Recent research

  1. Challenges and Possible Solutions to Direct-Acting Oral Anticoagulants (DOACs) Dosing in Patients with Extreme Bodyweight and Renal Impairment. Nwanosike, E. M., Sunter, W., Merchant, H. A., Conway, B.R., Ansari, M. A. & Hasan, S. S., 1 Jan 2023, In: American Journal of Cardiovascular Drugs. 23, 1, p. 9-17 9 p.
  2. A Real-World Exploration into Clinical Outcomes of Direct Oral Anticoagulant Dosing Regimens in Morbidly Obese Patients Using Data-Driven Approaches. Nwanosike, E., Sunter, W., Ansari, M. A., Merchant, H., Conway, B. & Hasan, S. S., 1 May 2023, In: American Journal of Cardiovascular Drugs. 23, 3, p. 287-299 13 p.
  3. Gravimetric assessment of postpartum blood loss: training and implementation in a low resource setting. Indrayani., Stacey, T., Merchant, H. & Darwin, Z., 1 Mar 2023, In: Australian Journal of Advanced Nursing. 40, 1, p. 21-29 9 p.

PUBLICATIONS

Patents

  1. Abdelsadig, M., Ghori, M. U., Conway, B. & Merchant, H., (2020), Natural plant-based coatings to improve the delivery and efficacy of nutraceuticals and traditional medicines. UKPTO, Patent Application No. GB2009780.4, Priority date: 26 June 2020
  2. Merchant, H, Farzand, R., Olajide, M. (2019) “Medicament for the inflammatory conditions of the skin”. UKPTO, Patent Application No. 2019464.3, Priority date: 11 Nov 2019 (in PCT).
  3. Merchant H., Frost, J., Basit, A. (2019) “Apparatus and method for testing medicaments" UK Granted Patent GB2509286B. Priority Date: 2nd May 2012; Granted: 5th Nov 2014 US Granted Patent US10234467B2. Priority Date: 2 May 2012; Granted: 19 March 2019 EU Patent EP2844999B1. Priority Date: 2 May 2012; Granted: 26 February 2020

Book Chapters

  1. Merchant H.A., 2022. Basic Pharmacokinetics. In. Biopharmaceutics, Fundamentals to Industrial Practice, Wiley International, p.9-29
  2. Sauer, J-M. & Merchant, H., 2018, Physiology of the Gastrointestinal System, Comprehensive Toxicology. McQueen, C. (ed.). 3rd ed. Elsevier, p. 16-44 29

Research Publications

2023

  • Nwanosike, E. M., Sunter, W., Merchant, H. A., Conway, B. R., Ansari, M. A. & Hasan, S. S., (2023) Challenges and Possible Solutions to Direct-Acting Oral Anticoagulants (DOACs) Dosing in Patients with Extreme Bodyweight and Renal Impairment. American Journal of Cardiovascular Drugs. 23, 1, p. 9-17 9 https://doi.org/10.1007/s40256-022-00560-7
  • Nwanosike, E., Sunter, W., Ansari, M. A., Merchant, H., Conway, B., & Hasan, S. S. (2023). A real-world exploration into clinical outcomes of direct oral anticoagulant (DOAC) dosing regimens in morbidly obese patients using data-driven approaches. American Journal of Cardiovascular Drugs, https://doi.org/10.1007/s40256-023-00569-6.
  • Indrayani, I., Stacey, T., Merchant, H., & Darwin, Z (2023). Gravimetric assessment of postpartum blood loss: training and implementation in a low resource setting. Australian Journal of Advanced Nursing, 40(1), 21-29. https://doi.org/10.37464/2023.401.693

2022

  • Mai, Y., Madla, C. M., Shao, H., Qin, Y., Merchant, H., Murdan, S., & Basit, A. W. (2022). Sex-specific effects of excipients on oral drug bioavailability. International Journal of Pharmaceutics, 629, [122365]. https://doi.org/10.1016/j.ijpharm.2022.122365
  • Merchant, H. (2022). The synergistic combination of trimetazidine, hypoxen and L-carnitine in endurance sports. British Journal of Pharmacy, 7(1), [1303]. https://doi.org/10.5920/bjpharm.1303
  • Merchant, H. (2022). A dengue-like outbreak of unknown aetiology in Pakistan. Tropical Medicine and Health, 50(1), [35]. https://doi.org/10.1186/s41182-022-00426-3
  • Merchant, H., Babar, Z-U-D., & Hussain, I. (2022). A leap towards enforcing medicines prescribing by generic names in low- and middle-income countries (LMICs): pitfalls, limitations, and recommendations for local drug regulatory agencies. Journal of Pharmaceutical Policy and Practice, 15(1), [104]. https://doi.org/10.1186/s40545-022-00501-4
  • Nwanosike, E. M., Sunter, W., Merchant, H. , Conway, B. R., Ansari, M. A., & Hasan, S. S. (2022). Challenges and Possible Solutions to Direct-Acting Oral Anticoagulants (DOACs) Dosing in Patients with Extreme Bodyweight and Renal Impairment. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-022-00560-7
  • Merchant, H. (2022). Comment on Aldén et al. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. Curr. Issues Mol. Biol. 2022, 44, 1115–1126. Current Issues in Molecular Biology, 44(4), 1661-1663. https://doi.org/10.3390/cimb44040113
  • Mustafa, Z. U., Bashir, S., Shahid, A., Raees, I., Salman, M., Merchant, H., Aldeyab, M. A., Kow, C. S., & Hasan, S. S. (2022). COVID-19 Vaccine Hesitancy among Pregnant Women Attending Antenatal Clinics in Pakistan: A Multicentric, Prospective, Survey-Based Study. Viruses, 14(11), [2344]. https://doi.org/10.3390/v14112344
  • Hasan, S. S., Rashid, A., Osama, S., Mustafa, Z. U., & Merchant, H. (2022). Covid-19 Vaccine safety and adverse event analysis from Pakistan. Clinical Immunology Communications, 2, 91-97. https://doi.org/10.1016/j.clicom.2022.05.003
  • Nwanosike, E. M., Conway, B. R., Merchant, H., & Hasan, S. S. (2022). Potential applications and performance of machine learning techniques and algorithms in clinical practice: A systematic review. International Journal of Medical Informatics, 159, [104679]. https://doi.org/10.1016/j.ijmedinf.2021.104679
  • Merchant, H. (2022). Why COVID vaccines for young children (5–11 years) are not essential at this moment in time? Journal of Pharmaceutical Policy and Practice, 15(1), [25]. https://doi.org/10.1186/s40545-022-00424-0
  • Hasan, S. S., Mustafa, Z. U., Kow, C. S., & Merchant, H. (2022). “Sehat Sahulat Program”: A Leap into the Universal Health Coverage in Pakistan. International Journal of Environmental Research and Public Health, 19(12), [6998]. https://doi.org/10.3390/ijerph19126998

2021

  • Ali, A. S., Hasan, S. S., Kow, C. S., & Merchant, H. (2021). Lactoferrin reduces the risk of respiratory tract infections: A meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN, 45, 26-32. https://doi.org/10.1016/j.clnesp.2021.08.019
  • Madla, C. M., Gavins, F. K. H., Merchant, H., Orlu, M., Murdan, S., & Basit, A. W. (2021). Let's Talk About Sex: Differences in Drug Therapy in Males and Females. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2021.05.014
  • Merchant, H. (2021). Inadvertent injection of COVID-19 vaccine into deltoid muscle vasculature may result in vaccine distribution to distance tissues and consequent adverse reactions. Postgraduate Medical Journal, [141119]. https://doi.org/10.1136/postgradmedj-2021-141119
  • Hasan, S. S., Kow, C. S., Mustafa, Z. U., & Merchant, H. A. (2021). Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials. Expert Review of Respiratory Medicine. https://doi.org/10.1080/17476348.2021.1925546
  • Kow, C. S., Merchant, H., Mustafa, Z. U., & Hasan, S. S. (2021). The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacological Reports. https://doi.org/10.1007/s43440-021-00245-z
  • Kow, C. S., Merchant, H., & Hasan, S. S. (2021). Mortality risk in patients infected with SARS-CoV-2 of the lineage B.1.1.7 in the UK. Journal of Infection. https://doi.org/10.1016/j.jinf.2021.05.008 Merchant, H. (2021). Autoimmune damage to the nerves following Covid vaccines: EMA issued warning to patients and healthcare professionals. The BMJ, 374, [bmj.n1786/rr-0]. https://www.bmj.com/content/374/bmj.n1786/rr-0
  • Merchant, H. (2021). Myocarditis followed by CoViD-19 vaccines: A cause for concern or a reversible minor effect? The BMJ, 373, n1244/rr-10. https://www.bmj.com/content/373/bmj.n1244/rr-10
  • Merchant, H. (2021). CoViD vaccines and thrombotic events: EMA issued warning to patients and healthcare professionals. Journal of Pharmaceutical Policy and Practice, 14(1), https://doi.org/10.1186/s40545-021-00315-w
  • Merchant, H. (2021). CoViD-19 post-vaccine menorrhagia, metrorrhagia or postmenopausal bleeding and potential risk of vaccine-induced thrombocytopenia in women. The BMJ. 373, bmj.n958/rr-2
  • Merchant, H. (2021). Might post-injection distribution of CoViD vaccines to the brain explain the rare fatal events of cerebral venous sinus thrombosis (CVST)? The BMJ. 373, bmj.n958/rr-1
  • Merchant, H. (2021). Can post immunisation increase in acute phase proteins explain the recent thrombotic events with CoViD vaccines? The BMJ. 373, bmj.n883/rr-1
  • Rabeea, S.A., Merchant, H., Khan, M.U. Know, C.S., Hasan, S.H. (2021). Surging trends in prescriptions and costs of antidepressants in England amid COVID-19. DARU J Pharm Sci. https://doi.org/10.1007/s40199-021-00390-z
  • Merchant, H. (2021). Response to: COVID vaccines and thrombotic events: is mRNA translation and spike protein synthesis by platelets a real possibility? The BMJ, 372, bmj.n699/rr-20
  • Merchant, H., Kow, C. S. & Hasan, S. S., (2021) COVID-19 first anniversary review of cases, hospitalization, and mortality in the UK. Expert Review of Respiratory Medicine. https://doi.org/10.1080/17476348.2021.1890035
  • Merchant, H., (2021). CoViD Vaccines and thrombotic events: Possibility of mRNA translation and spike protein synthesis by platelets? The BMJ. 372, n699/rr-6.
  • Afzal, S., Zaidi, S. T. R., Merchant, H., Babar, Z. & Hasan, S. S., (2021). Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting, Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-021-02416-4

2020

  • Merchant, H., (2020). Coronavirus may stay with us forever! The BMJ. 369, 1 p., m1790/rr-6.
  • Merchant, H., (2020). CoViD-19: An early intervention therapeutic strategy to prevent developing a severe disease as an alternative approach to control the pandemic, ScienceOpen (Preprint), https://doi.org/10.14293/S2199-1006.1.SOR-.PPURWMT.v1
  • Merchant, H., (2020). CoViD-19: Pharmaceutical care during early disease. The BMJ. 369, bmj.m2035/rr-2. Merchant, H., (2020). CoViD-19 may not end as predicted by the SIR model. The BMJ. 369, m1567/rr.
  • Merchant, H., Kow, C. S. & Hasan (2020), Dexamethasone and CoViD-19: RECOVERY trial provided invaluable clinical evidence but costed precious lives! The BMJ, m2422/rr-10
  • Nirwan, J., Farhaj, S., Chaudhary, M. M., Khizer, Z., Hasan, S. S., Angelis-Dimakis, A., Gill, A., Rasheed, H., Abbas, N., Arshad, M. S., Hussain, T., Shahzad, Y., Yousaf, A., Chohan, T. A., Hussain, T., Merchant, H., Akram, M. R., Khan, T. M., Ashraf, M., Conway, B. & Ghori, M.U. (2020). Exploration of a New Source of Sustainable Nanomaterial from the Koh-e-Suleiman Mountain Range of Pakistan for Industrial Applications. Scientific Reports. 10, 1, 14 p., 577.
  • Beradi, A., Perinelli, D., Merchant, H., Bisharat, L., Basheti, I., Bonacucina, G., Cespi, M. & Palmieri, G., (2020), Hand sanitisers amid CoViD-19: A critical review of alcohol-based products on the market and formulation approaches to respond to increasing demand. International Journal of Pharmaceutics. 584, 14 p., 119431.
  • Hasan, S. S., Kow, C. S. & Merchant, H., (2020). Is it worth the wait? Should Chloroquine or Hydroxychloroquine be allowed for immediate use in CoViD-19? British Journal of Pharmacy. 5, 1, 5 p., 745.
  • Hasan, S. S., Kow, C. S., Hadi, M. A., Zaidi, S. T. R. & Merchant, H., (2020). Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis. American Journal of Cardiovascular Drugs. 20, 6, p. 571-590 20
  • Hasan, S. S., Capstick, T., Ahmed, R., Kow, C. S., Mazhar, F., Merchant, H. & Zaidi, S. T. R., (2020). Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Review of Respiratory Medicine. 14, 11, p. 1149-1163
  • Hasan, S. S., Kow, C. S., Bain, A., Kavanagh, S., Merchant, H. & Abdul Hadi, M., (2020). Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients. Expert Opinion on Pharmacotherapy. doi: 10.1080/14656566.2020.1837114
  • Merchant, H., (2020). Response to: Covid-19: trials of four potential treatments to generate “robust data” of what works. The BMJ. 1 p., m1206/rr-1.
  • Hasan, S. S., Capstick, T., Razi Zaidi, S. T., Kow, C. S. & Merchant, H., (2020). Use of corticosteroids in asthma and COPD patients with or without COVID-19. Respiratory Medicine. 170, 5 p., 106045.
  • Mazhar, F., Abdul Hadi, M., Kow, C. S., Marran, A. M. N., Merchant, H. & Hasan, S. S., (2020). Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? International Journal of Infectious Diseases. 101, p. 107-120 14 p.
  • Merchant, H., (2020), Why Pfizer's or Moderna's CoViD-19 vaccine cannot be 95% effective? The BMJ. bmj.m4471/rr-3.

2019

  • Barbosa J., Al-Kauraishi, M, Smith, A, Conway, BR and Merchant, H. (2019) ‘Achieving gastro-resistance without coating: formulation of capsule shells from enteric polymers’. European Journal of Pharmaceutics and Biopharmaceutics, European Journal of Pharmaceutics and Biopharmaceutics. 144, p. 174-179 6
  • Barbosa J., Abdelsadig MSE, Conway, BR and Merchant, H. (2019) ‘Using zeta potential to study the ionisation behaviour of polymers employed in modified-release dosage forms and estimating their pKa’. International Journal of Pharmaceutics X, 10.1016/j.ijpx.2019.100024

2018

  • Sauer, J. and Merchant, H. (2018) ‘Physiology of the Gastrointestinal System’. In: Comprehensive Toxicology (Third Edition), Elsevier. pp. 16-44. ISBN 9780081006016

2017

  • Conway, B. and Merchant, H. (2017) ‘Editorial: maintaining open access to high quality publications at no cost to authors’ British Journal of Pharmacy, 2 (1). ISSN 2058-8356
  • Ghori, M., Mohammad, M., Rudrangi, S., Fleming, L., Merchant, H., Smith, A. and Conway, B. (2017) ‘Impact of purification on physicochemical, surface and functional properties of okra biopolymer’ Food Hydrocolloids , 71, pp. 311-320. ISSN 0268-005X
  • Merchant, H. (2017) ‘Can Diet Help Non-Obese Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD)?’ Journal of Clinical Medicine, 6 (9). ISSN 2077-0383
  • Barbosa, J., Conway, B. and Merchant, H. (2017) ‘Going Natural: Using polymers from nature for gastroresistant applications’ British Journal of Pharmacy, 2 (1). ISSN 2058-8356

2016

  • Conway, B. and Merchant, H. (2016) ‘Foreword: BJPharm - a new Open Access Journal for Research, Education and Practice in Pharmacy’ British Journal of Pharmacy, 1 (1). ISSN 2058-8356
  • Merchant, H., Liu, F., Orlu Gul, M. and Basit, A. (2016) ‘Age-mediated changes in the gastrointestinal tract’ International Journal of Pharmaceutics, 512 (2), pp. 382-395. ISSN 0378-5173

2015

  • Hatton, G., Yadav, V., Basit, A. and Merchant, H. (2015) ‘Animal Farm: Considerations in Animal Gastrointestinal Physiology and Relevance to Drug Delivery in Humans’ J Pharm Sci, 104 (9), pp. 2747-2776. ISSN 0022-3549
  • Merchant, H., Afonso-Pereira, F., Rabbie, S., Youssef, S. and Basit, A. (2015) ‘Gastrointestinal characterisation and drug solubility determination in animals’ Journal of Pharmacy and Pharmacology, 67 (5), pp. 630-639. ISSN 0022-3573
  • Goyanes, A., Hatton, G., Merchant, H. and Basit, A. (2015) ‘Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations’ International Journal of Pharmaceutics, 484 (1-2), pp. 103-108. ISSN 03785173

2014

  • Merchant, H., Goyanes, A., Parashar, N. and Basit, A. (2014) ‘Predicting the gastrointestinal behaviour of modified-release products: Utility of a novel dynamic dissolution test apparatus involving the use of bicarbonate buffers’ International Journal of Pharmaceutics, 475 (1-2), pp. 585-591. ISSN 0378-5173
  • Merchant, H., Rabbie, S., Varum, F., Afonso-Pereira, F. and Basit, A. (2014) ‘Influence of ageing on the gastrointestinal environment of the rat and its implications for drug delivery.’ European Journal of Pharmaceutical Sciences, 62, pp. 76-85. ISSN 0928-0987
  • Varum, F., Merchant, H., Goyanes, A., Zboranov, V. and Basit, A. (2014) ‘Accelerating the dissolution of enteric coatings in the upper small intestine: Evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release.’ International Journal of Pharmaceutics, 468 (1-2), pp. 172-177. ISSN 03785173
  • Kaassis, A., Young, N., Sano, N., Merchant, H., Yu, D., Chatterton, N. and Williams, G. (2014) ‘Pulsatile drug release from electrospun poly(ethylene oxide)–sodium alginate blend nanofibres’ Journal of Materials Chemistry B (10), pp. 1400-14078. ISSN 2050-750X

2013

  • Yadav, V., Gaisford, S., Merchant, H. and Basit, A. (2013) ‘Colonic bacterial metabolism of corticosteroids.’ International Journal of Pharmaceutics, 457 (1), pp. 268-274. ISSN 03785173
  • Merchant, H., Frost, J. and Basit, A.(2013) Apparatus and methods for testing medicaments. US10234467B2 (March 2019), GB2509286B (November 2014).
  • Araujo, V., Gamboa, A., Caro, N., Abugoch, L., Gotteland, M., Valenzuela, F., Merchant, H., Basit, A. and Tapia, C. (2013) ‘Release of prednisolone and inulin from a new calcium-alginate chitosan-coated matrix system for colonic delivery.’ Journal of Pharmaceutical Sciences, 102 (8), pp. 2748-2759. ISSN 0022-3549

2011

  • Freire, A., Basit, A., Choudhary, R., Piong, C. and Merchant, H. (2011) ‘Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery.’ International Journal of Pharmaceutics, 415 (1-2), pp. 15-28. ISSN 03785173
  • Liu, F., Merchant, H., Kulkarni, R., Alkademi, M. and Basit, A. (2011) ‘Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products.’ Eur J Pharm Biopharm, 78 (1), pp. 151-157. ISSN 0939-6411
  • Merchant, H., McConnell, E., Liu, F., Ramaswamy, C., Kulkarni, R., Basit, A. and Murdan, S. (2011) ‘Assessment of gastrointestinal pH, fluid and lymphoid tissue in the guinea pig, rabbit and pig, and implications for their use in drug development.’ Eur J Pharm Sci, 42 (1-2), pp. 3-10. ISSN 0928-0987

2010

  • Varum, F., Merchant, H. and Basit, A. (2010) ‘Oral modified-release formulations in motion: the relationship between gastrointestinal transit and drug absorption.’ International Journal of Pharmaceutics, 395 (1-2), pp. 26-36. ISSN 03785173

2009

  • Fadda, H., Merchant, H., Arafat, B. and Basit, A. (2009) ‘Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems.’ International Journal of Pharmaceutics, 382 (1-2), pp. 56-60. ISSN 03785173

2006

  • Merchant, H., Shoaib, H., Tazeen, J. and Yousuf, R. (2006) ‘Once-daily tablet formulation and in vitro release evaluation of cefpodoxime using hydroxypropyl methylcellulose: a technical note.’ AAPS PharmSciTech , 7 (3), p. E178-E183. ISSN 1530-9932
  • Shoaib, M., Tazeen, J., Merchant, H. and Yousuf, R. (2006) ‘Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC.’ Pakistan Journal of Pharmaceutical Sciences, 19 (2), pp. 119-124. ISSN 1011-601X

EXTERNAL ROLES

Publications

The last four years of publications can be viewed below. 

Full publications list

Visit the research repository to view a full list of publications

Research repository